| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
ATAI Life Sciences N.V. Common Shares (NASDAQ: ATAI)
ATAI Technical Analysis
5
| As on 9th Jun 2023 ATAI STOCK Price closed @ 1.75 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 4.49 & Strong Sell for SHORT-TERM with Stoploss of 6.10 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ATAISTOCK Price
| Open | 1.78 | Change | Price | % |
| High | 1.83 | 1 Day | -0.04 | -2.23 |
| Low | 1.74 | 1 Week | -0.02 | -1.13 |
| Close | 1.75 | 1 Month | -0.11 | -5.91 |
| Volume | 372921 | 1 Year | -6.24 | -78.10 |
| 52 Week High 8.34 | 52 Week Low 1.17 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ATAI Daily Charts |
ATAI Intraday Charts |
Whats New @ Bazaartrend |
ATAI Free Analysis |
|
|
ATAI Important Levels Intraday
| RESISTANCE | 1.92 |
| RESISTANCE | 1.87 |
| RESISTANCE | 1.83 |
| RESISTANCE | 1.80 |
| SUPPORT | 1.70 |
| SUPPORT | 1.67 |
| SUPPORT | 1.63 |
| SUPPORT | 1.58 |
ATAI Forecast April 2024
| 4th UP Forecast | 6.78 |
| 3rd UP Forecast | 5.17 |
| 2nd UP Forecast | 4.17 |
| 1st UP Forecast | 3.17 |
| 1st DOWN Forecast | 0.33 |
| 2nd DOWN Forecast | -0.67 |
| 3rd DOWN Forecast | -1.67 |
| 4th DOWN Forecast | -3.28 |
ATAI Weekly Forecast
| 4th UP Forecast | 4.10 |
| 3rd UP Forecast | 3.35 |
| 2nd UP Forecast | 2.88 |
| 1st UP Forecast | 2.41 |
| 1st DOWN Forecast | 1.09 |
| 2nd DOWN Forecast | 0.62 |
| 3rd DOWN Forecast | 0.15 |
| 4th DOWN Forecast | -0.60 |
ATAI Forecast2024
| 4th UP Forecast | 16.11 |
| 3rd UP Forecast | 11.5 |
| 2nd UP Forecast | 8.66 |
| 1st UP Forecast | 5.81 |
| 1st DOWN Forecast | -2.31 |
| 2nd DOWN Forecast | -5.16 |
| 3rd DOWN Forecast | -8 |
| 4th DOWN Forecast | -12.61 |
ATAI Life Sciences N.V. Common Shares ( NASDAQ USA Symbol : ATAI )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ATAI Business Profile
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that are focused on multiple mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a GABA/nicotinic modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany. Address: Krausenstrasse 9-10, Berlin, Germany, 10117
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service